tbuckley/cabot-search huggingface dataset:
Occupational exposure to textile dust increases the risk of rheumatoid arthritis: results from a Malaysian population-based case–control study
Authors: Chun Lai Too, Nor Asiah Muhamad, Anna Ilar, Leonid Padyukov, Lars Alfredsson, Lars Klareskog, Shahnaz Murad, Camilla Bengtsson
Journal: Annals of the Rheumatic Diseases (2015)

Objectives Lung exposures including cigarette smoking and silica exposure are associated with the risk of rheumatoid arthritis (RA). We investigated the association between textile dust exposure and the risk of RA in the Malaysian population, with a focus on women who rarely smoke. Methods Data from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis population-based case–control study involving 910 female early RA cases and 910 female age-matched controls were analysed. Self-reported information on ever/never occupationally exposed to textile dust was used to estimate the risk of developing anti-citrullinated protein antibody (ACPA)-positive and ACPA-negative RA. Interaction between textile dust and the human leucocyte antigen DR β-1 (HLA-DRB1) shared epitope (SE) was evaluated by calculating the attributable proportion due to interaction (AP), with 95% CI. Results Occupational exposure to textile dust was significantly associated with an increased risk of developing RA in the Malaysian female population (OR 2.8, 95% CI 1.6 to 5.2). The association between occupational exposure to textile dust and risk of RA was uniformly observed for the ACPA-positive RA (OR 2.5, 95% CI 1.3 to 4.8) and ACPA-negative RA (OR 3.5, 95% CI 1.7 to 7.0) subsets, respectively. We observed a significant interaction between exposure to occupational textile dust and HLA-DRB1 SE alleles regarding the risk of ACPA-positive RA (OR for double exposed: 39.1, 95% CI 5.1 to 297.5; AP: 0.8, 95% CI 0.5 to 1.2). Conclusions This is the first study demonstrating that textile dust exposure is associated with an increased risk for RA. In addition, a gene–environment interaction between HLA-DRB1 SE and textile dust exposure provides a high risk for ACPA-positive RA.
Abstract 11935: Feasibility and Security of Transradial Coronary Intervention Using 6.5 French Sheathless Guiding Catheter in Patients With Small Radial Artery
Authors: Radi M Cheaito, Hakim Benamer, Yves Louvard, Hazrije Mustafic, Youssef Derraz, Oscar Tavolaro, Thomas Hovasse, Cedric Gaultier, Philippe Garot, Thierry Lefevre, Marie Claude Morice
Journal: Circulation (2012)

Background and Objectives: For patient comfort and security, transradial coronary angiography is more frequently. This access is associated with lower major vascular access site complications. Howe...
A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
Authors: J L Grem, N McAtee, R F Murphy, F M Balis, S M Steinberg, J M Hamilton, J M Sorensen, O Sartor, B S Kramer, L J Goldstein
Journal: Journal of Clinical Oncology (1991)

Thirty-one assessable patients with metastatic adenocarcinoma of the gastrointestinal tract were entered onto a pilot study designed to assess the impact of recombinant interferon alpha-2a (rIFN alpha-2a) on the toxicity and pharmacokinetics of fluorouracil (5-FU) and leucovorin (LV). Patients received an initial cycle of 5-FU (370 or 425 mg/m2/d) with LV (500 mg/m2/d) for 5 days. If tolerated, the patient received the same dose of 5-FU/LV for the second cycle on days 2 to 6, with rIFN alpha-2a at 5 x 10(6) or 10 x 10(6) U/m2/d on days 1 to 7, or with 3 x 10(6) U/m2/d on days 1 to 14. In 26 matched cycles, rIFN alpha-2a administration was associated with an increased incidence of dose-limiting mucositis and diarrhea and a significantly lower median platelet nadir; rIFN alpha-2a did not significantly affect the median WBC or granulocyte nadir. Dose-limiting toxicity occurred in all six patients entered at 425 mg/m2/d of 5-FU/LV within two cycles. The majority of patients treated with 370 mg/m2/d of 5-FU/LV and 10 x 10(6) U/m2/d rIFN alpha-2a experienced grade 3 to 4 mucositis and diarrhea, whereas patients receiving 3 x 10(6) and 5 x 10(6) U/m2/d rIFN alpha-2a had acceptable toxicity. Administration of rIFN alpha-2a was associated with a dose-dependent decrease in 5-FU clearance. The increase in the area under the 5-FU concentration-time curve (AUC) was 1.3-fold and 1.5-fold in patients receiving 5 x 10(6) and 10 x 10(6) U/m2/d rIFN alpha-2a, respectively. Thus, the increase in 5-FU toxicity with rIFN alpha-2a may be explained by alterations in 5-FU pharmacokinetics. In 22 patients without prior 5-FU therapy, three complete (13.6%) and seven partial (31.8%) responses were seen, for an overall response rate of 45.4% (95% confidence interval, 24.4% to 67.8%). Since the 5 x 10(6) U/m2/d dose of rIFN alpha-2a increased the 5-FU drug exposure and was associated with acceptable toxicity, we recommend its further evaluation as given on days 1 to 7 in combination with 5-FU 370 mg/m2/d, with high-dose LV given on days 2 to 6.
Clinical significance of Cdh1-Skp2 cascade in breast cancer
Authors: T. Fujita, G. Wu, R. D. Wood, Y. Wan
Journal: Journal of Clinical Oncology (2007)

10609 Background: Skp2 (S-phase kinase-associated protein 2) is substrate-recognizing subunit of an ubiquitin E3 ligase SCF (Skp1, Cullin and F-box) complex and has a major role in p27 regulation. Overexpression of Skp2 is frequently seen in human tumors, often correlating with poor prognosis. Anaphase-promoting complex/cyclosome (APC/C) is another most prominent ubiquitin E3 ligase in cell cycle control, and its function is tightly controlled by activating subunit Cdh1 (Fizzy-related). APC-Cdh1 complex is supposed to be involved in Skp2 proteolysis and have essential role for S phase entry, however clinical significance of Cdh1 have not evaluated yet. Herein we examined the significance of Cdh1 in breast cancer. Methods: Firstly, MCF7 human breast cancer cells and MCF10A normal breast epithelial cells were analyzed in vitro and in vivo. Thereafter, using tissue microarray, we evaluate the expression profile of Cdh1, Skp2 and p27 in both breast cancer and normal breast epithelial tissue. Moreover, clinicopathological significance (age, tumor size, lymph node metastasis, distant metastasis, histological grade, and stage) of Cdh1 was analyzed from 126 breast cancer patients. Chi square-test, Fisher's exact test were used for statistical analysis of immunostaining results and clinicopathological data. p&lt;0.05 was considered statistically significant. Results: Overexpression of Cdh1 induced attenuation of Skp2 and increased p27 protein expression, resulted in growth suppression. Moreover, knockdown of Cdh1 promoted higher Skp2 expression and S-phase population, reduced p27 and consequently induced cell transformation and proliferation in vitro and in vivo. Tissue microarray results appeared that positive Cdh1 and p27 was more frequently seen in normal breast tissue and statistically significant. On the other hand, Skp2 was less in normal tissue. Furthermore, Cdh1 positive breast cancer was more frequently seen in low histological grade tumors and statistically significant (p=0.04). Conclusions: Skp2 protein expression is regulated by Cdh1 in breast cancer. Cdh1 expression could be possible novel biomarker in patient with breast cancer. No significant financial relationships to disclose.
Phase II study of Gemcitabine and Curcumin (Meriva®) as first line treatment for locally advanced or metastatic pancreatic cancer: preliminary results
Authors: C. Soldà, R. Bardini, C. Sperti, G. Da Dalt, M. Gion, P. Fiduccia, F. Ursini, C. Aliberti, D. Pastorelli
Journal: Annals of Oncology (2015)
Abstract 19535: Impact of Proximal Anastomotic Site on the Patency of Free Internal Thoracic and Radial Artery in Coronary Artery Bypass Grafting-Y Composite Grafting v.s Aorto-Coronary Bypass
Authors: Jiro Sakai, Takeshi Shimamoto, Gen-ichi Sakaguchi, Tatsuhiko Komiya
Journal: Circulation (2010)

Background: Arterial grafts such as right internal thoracic artery (RITA) and radial artery(RA) has been used as second graft with various configuration. The aim of this study was to compare the ar...
Abstract 14544: The Association of Inflammation with Obesity and Depressive Symptoms among People with Multiple Cardiovascular Disease Risk Factors
Authors: Kyoung Suk Lee, Terry A Lennie, John Novak, Baretta Casey, Gia Mudd, Alison L Bailey, Debra K Moser
Journal: Circulation (2012)

Background: Obesity and depression are associated with inflammation. Inflammation is a biological mechanism underlying cardiovascular disease (CVD). Obese people with depression may be at a greater...
A comparison of computed tomography and radionuclide scanning for detection of brain metastases in small cell lung cancer.
Authors: J M Crane, M J Nelson, D C Ihde, R W Makuch, E Glatstein, A Zabell, A Johnston-Early, H R Bates, N Saini, M H Cohen
Journal: Journal of Clinical Oncology (1984)

Neurologic history and examination, radionuclide brain scans (RN), and computed tomographic brain scans (CT) were performed at diagnosis and sequentially in 153 consecutive patients with small cell lung cancer (SCLC) to assess the sensitivity and accuracy of these screening methods and to determine whether the early detection of brain metastases influences survival. CT scans (sensitivity, 98%; positive predictive accuracy, 98%) were superior to RN scans (sensitivity, 71%; positive predictive accuracy, 86%) in patients with or without neurologic signs or symptoms. However, CT scans were positive in only 6% of asymptomatic patients at diagnosis and 13% of asymptomatic patients after systemic therapy. Brain metastases detected by CT scan were the sole site of extensive-stage disease in 6% of patients at diagnosis. Despite the enhanced ability of CT scans to detect asymptomatic lesions, survival after therapeutic cranial irradiation was similar for asymptomatic and symptomatic patients. The results suggest that CT brain scans should be used routinely in SCLC patients with neurologic signs or symptoms, at diagnosis (when treatment decisions are based on stage), and at six-month intervals in patients with prior brain metastases and in whom erratic follow-up is likely.
Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer
Authors: David R. Kroeger, Katy Milne, Brad H. Nelson
Journal: Clinical Cancer Research (2016)

CD8(+) tumor-infiltrating lymphocytes (TIL) are key mediators of antitumor immunity and are strongly associated with survival in virtually all solid tumors. However, the prognostic effect of CD8(+) TIL is markedly higher in the presence of CD20(+) B cells, suggesting that cooperative interactions between these lymphocyte subsets lead to more potent antitumor immunity.We assessed the colocalization patterns, phenotypes, and gene expression profiles of tumor-associated T- and B-lineage cells in high-grade serous ovarian cancer (HGSC) by multicolor IHC, flow cytometry, and bioinformatic analysis of gene expression data from The Cancer Genome Atlas.T cells and B cells colocalized in four types of lymphoid aggregate, ranging from small, diffuse clusters to large, well-organized tertiary lymphoid structures (TLS) resembling activated lymph nodes. TLS were frequently surrounded by dense infiltrates of plasma cells (PC), which comprised up to 90% of tumor stroma. PCs expressed mature, oligoclonal IgG transcripts, indicative of antigen-specific responses. PCs were associated with the highest levels of CD8(+), CD4(+), and CD20(+) TIL, as well as numerous cytotoxicity-related gene products. CD8(+) TIL carried prognostic benefit only in the presence of PCs and these other TIL subsets. PCs were independent of mutation load, BRCA1/2 status, and differentiation antigens but positively associated with cancer-testis antigens.PCs are associated with the most robust, prognostically favorable CD8(+) TIL responses in HGSC. We propose that TLS facilitate coordinated antitumor responses involving the combined actions of cytolytic T cells and antibody-producing PCs. Clin Cancer Res; 22(12); 3005-15. ©2016 AACR.
Suicide Attempts in the US Army
Authors: Christopher G. Ivany, Charles W. Hoge
Journal: JAMA Psychiatry (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Angiotensin-I-converting enzyme in cancer patients.
Authors: C M Mansfield, B F Kimler, S D Henderson, T S Vats, D J Svoboda
Journal: Journal of Clinical Oncology (1984)

Serum levels of angiotensin-I-converting enzyme (ACE) were assayed before, during, and after radiation therapy in 209 patients receiving treatment for neoplastic disease. Daily fluctuations in the measured ACE levels were minimized by comparing all patient values to that of a simultaneously run sample from a standard source of serum obtained by pooling sera from young, healthy volunteers. Most of the patients tested presented with a normal to low ACE level, with the mean value for all patients being 70% of the standard value. More patients with primary lung cancer displayed values that were low (107 of 120) than did patients with disease outside the lung (44 of 78), this difference being statistically significant at p less than 0.001. In addition, more patients with lung cancer had values less than 70% of the standard than did patients with disease outside the lungs. These initial results suggest that monitoring of serum ACE levels may be useful in the management of patients with malignant disease in the lung.
Abstract 11119: Safety and Effectiveness of Cardiac Catheterization Within 24 Hours of Admission in Cardiac Arrest Patients Treated With Mild Therapeutic Hypothermia
Authors: Anushree Agarwal, Tonga Nfor, Mahek Mirza, Arshad Jahangir, Anjan Gupta, Suhail Allaqaband
Journal: Circulation (2012)

Introduction: The use of mild therapeutic hypothermia (MTH) post-cardiac arrest is increasing; however, there is reluctance to combine early cardiac catheterization with MTH. Hypothesis: This study...
Retrospective analysis with metronomic chemotherapy in patients with metastatic renal cell carcinoma.
Authors: E. Tellez Bernal, M. J. Rios, M. A. Avitia, L. S. Nateras, C. D. Romero, R. M. Moreno, D. O. Caraza, D. S. Hernandez
Journal: Journal of Clinical Oncology (2010)

e15144 Background: Treatment of metastatic kidney cancer is based on antiangiogenic therapy; although this treatment is expensive and secondary effects could be important. There are many ways to block angiogenic process, metronomic chemotherapy is one of them. We evaluate response to metronomic chemotherapy as well toxicity. Methods: Patients characteristics: We analyzed medical records with kidney cancer,all patients received at least 3 cycles of the treatment. All patients where classified according to Motzer criteria: good/ intermediate/poor prognosis were: 6/6/1 respectively. Response according to RECIST were: Partial response 3 pts (23.7 %) one patient with good prognostic and two intermediate, stable disease in 7 (53.84 %) (4 good and 3 intermediate prognosis), progression disease were in 3 patients (1 with good, 2 with poor prognosis). In 84% patients we noted clinical benefit with tree cycles. The median time to disease progression for the entire group was 8 months (range, 1-11 mos), with a median overall survival of 11 months (range 2-24mos). The toxicity grade 3-4 reported was in 3 patients: gastrointestinal, dermatological, and febrile neutropenia. Additional patients had reversible toxicities grade 1-2 including alopecia, nausea, vomiting, and fatigue in 90% of the cases. Results: Metronomic chemotherapy is a good therapeutic option in patients with metastatic kidney cancer with acceptable response rate. Conclusions: Metronomic chemotherapy is a good therapeutic option in patients with metastatic kidney cancer with acceptable response rate. No significant financial relationships to disclose.
Bilateral absent uterine arteries
Authors: Zeinab Abou Yehia, Walid Faraj, Dalia Morad, Albert El Hajj, Ali Haydar
Journal: BMJ (2016)

A 52 year old woman presented with right flank pain and dysuria. Pelvic ultrasound showed a large uterine leiomyoma. Fibroid embolisation versus …
Piwi-interacting RNAs in cancer: emerging functions and clinical utility
Authors: Kevin W. Ng, Christine Anderson, Erin A. Marshall, Brenda C. Minatel, Katey S. S. Enfield, Heather L. Saprunoff, Wan L. Lam, Victor D. Martinez
Journal: Molecular Cancer (2016)

PIWI-interacting RNAs (piRNAs) are emerging players in cancer genomics. Originally described in the germline, there are over 20,000 piRNA genes in the human genome. In contrast to microRNAs, piRNAs interact with PIWI proteins, another member of the Argonaute family, and function primarily in the nucleus. There, they are involved in the epigenetic silencing of transposable elements in addition to the transcriptional regulation of genes. It has recently been demonstrated that piRNAs are also expressed across a variety of human somatic tissue types in a tissue-specific manner. An increasing number of studies have shown that aberrant piRNA expression is a signature feature across multiple tumour types; however, their specific tumorigenic functions remain unclear. In this article, we discuss the emerging functional roles of piRNAs in a variety of cancers, and highlight their potential clinical utilities.
Inhibition of lung inflammation by a protein epitope mimetic (PEM) neutrophil elastase inhibitor, POL6014, in a sub-chronic tobacco smoke (TS) model in mice
Authors: Odile Sellier-Kessler, Michel Schmitt, Achim Wach, Eric Chevalier
Journal: European Respiratory Journal (2013)

Rationale:  Neutrophil elastase (NE) plays a central role in inflammation and tissue degradation in airway diseases, e.g. alpha-1 antitrypsin deficiency, cystic fibrosis and chronic obstructive pulmonary disease. Its inhibition might therefore be of use to improve the current treatments for those diseases.   Objective:  The aim of the study was to evaluate the effect of a direct lung application of POL6014, a potent NE inhibitor, in a 4 day TS model in mice.   Methods : POL6014 (0.1, 0.5, 2 and 10 mg/kg) or a positive control, p38 inhibitor (0.1 mg/kg) were intranasally administered daily 1 h before each TS exposure in C57BL/6j mice for 4 days. The bronchoalveolar lavage (BAL) fluid was collected 24 h after the end of the last TS exposure and the total and differential cell counts were determined. Plasma and lung compound levels were also measured.   Results:  POL6014 dose-dependently and significantly reduced the number of macrophages, epithelial cells, neutrophils and lymphocytes recovered in BAL. The maximum inhibition was reached at 2 mg/kg in reducing neutrophils by 65% (p  At 0.1 mg/kg POL6014 already showed significant inhibition on neutrophils by 50% (p  POL6014 showed dose-related exposures with substantial lung and low plasma levels and no accumulation after repeated administration.   Conclusion:  POL6014 significantly and dose-dependently reduced TS-induced inflammation. It might provide a new therapeutic approach for the treatment of NE-driven lung diseases.
Cancer-Related Fatigue
Authors: Victoria Mock, Ashley Atkinson, Andrea M Barsevick, Ann M Berger, Bernadine Cimprich, Mario A Eisenberger, Pamela Hinds, Phyllis Kaldor, Shirley A Otis-Green, Barbara F Piper
Journal: Journal of the National Comprehensive Cancer Network (2007)

Fatigue is a common symptom in patients with cancer and is nearly universal in those undergoing cytotoxic chemotherapy, radiation therapy, bone marrow transplantation, or treatment with biologic response modifiers. The problem, which affects 70% to 100% of cancer patients, has been exacerbated by the increased use of fatigue-inducing multimodal treatments and dose-dense, dose-intense protocols. In patients with metastatic disease, the prevalence of cancer-related fatigue exceeds 75%, and cancer survivors report that fatigue is a disruptive symptom months or even years after treatment ends. Patients perceive fatigue to be the most distressing symptom associated with cancer and its treatment, more distressing even than pain or nausea and vomiting, which, for most patients, can generally be managed with medications. For the most recent version of the guidelines, please visit NCCN.org
Marrow cytogenetic and cell-culture analyses of the myelodysplastic syndromes: insights to pathophysiology and prognosis.
Authors: E J Gold, M Conjalka, L M Pelus, S C Jhanwar, H Broxmeyer, A B Middleton, B D Clarkson, M A Moore
Journal: Journal of Clinical Oncology (1983)

Marrow cytogenetic and granulocyte-macrophage colony formation (CFU-GM) studies were performed on 34 previously untreated patients with documented myelodysplastic syndromes seen between January 1978 and June 1982. All patients were managed without chemotherapy until progression to acute leukemia was observed. All 10 patients with exclusively abnormal marrow metaphases developed acute leukemia (100%) while only one (7%) of 14 patients with solely normal marrow metaphases subsequently developed leukemia (p less than 0.001). Three (42%) of the seven patients with both normal and abnormal marrow metaphases developed acute leukemia. Fifteen (86%) of the 19 patients with either large cluster or no growth patterns developed acute leukemia while only two (13%) of 15 patients with either small cluster or colony forming growth patterns developed acute leukemia (p less than 0.001). Abnormal marrow cytogenetic status correlated with abnormal marrow CFU-GM growth pattern (p less than 0.05). Analysis of CFU-GM sensitivity to inhibition by prostaglandin E was performed in 12 patients. Nine patients showed CFU-GM refractoriness to inhibition by prostaglandin E. Seven of these patients eventually developed leukemia. Three patients had CFU-GMs which were initially sensitive to prostaglandin E inhibition. In these three patients, a loss of CFU-GM sensitivity to prostaglandin E was observed prior to their progression to morphologically identifiable acute leukemia.